Michael Pishvaian, MD, PhD | Authors


Genetic Testing Should Be Considered for All Patients With Pancreatic Cancer

October 05, 2020

Michael J. Pishvaian, MD, PhD, discusses the key takeaway from his presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology on the role of genetic testing in patients with pancreatic cancer.

Clinical Benefit of Entrectinib for Patients With Metastatic Pancreatic Cancer

January 26, 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study investigating entrectinib in patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions.